Formalin-inactivated Venezuelan Equine Encephalomyelitis (Trinidad Strain) Vaccine Produced in Rolling-Bottle Cultures of Chicken Embryo Cells

FRANCIS E. COLE, JR., STEPHEN W. MAY, AND DAVID M. ROBINSON
U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21701

Received for publication 27 October 1972

Formalin-inactivated Venezuelan equine encephalomyelitis vaccine was prepared from virus grown in rolling-bottle cultures of chicken embryo cells. Trinidad strain virus was propagated in these cultures with a maintenance medium consisting of serum-free medium 199 containing 0.25% human serum albumin (USP) and antibiotics. Manipulation of multiplicity of inoculum (0.06 to 0.00006) and maintenance medium volume (100 to 300 ml) resulted in high-titered virus yields and only moderate cell destruction when fluids from infected cultures were harvested at 18 to 24 hr. The virus was inactivated at 37°C by 0.05% Formalin within 8 to 10 hr and with 0.1% Formalin within 6 to 8 hr. Single dose, antigen extinction tests in mice performed with 30 small-scale vaccine lots showed excellent potency at either Formalin concentration with inactivation periods ranging from 24 to 96 hr.

The need for an inactivated Venezuelan equine encephalomyelitis (VEE) vaccine is manifold. The currently employed attenuated (TC-83) VEE vaccine (4, 9), although highly protective, causes mild to moderate systemic reactions in 20 to 40% of human vaccinees (1; P. J. Bartelloni, personal communication). Based on our experience with inactivated Western and Eastern equine encephalomyelitis (WEE, EEE) vaccines in man (2, 3), one can anticipate that a VEE vaccine, similarly prepared, would be of equally low reactogenicity. Moreover, a VEE vaccine could be incorporated with existing inactivated WEE (2) and EEE (10) vaccines to achieve a trivalent product. This combined immunogen would be of logistical advantage for use in at-risk laboratory personnel or field personnel as well as for Equidae, the significant amplifying hosts for VEE.

The need for an inactivated VEE vaccine has been given greater impetus due to the presence of epizootic VEE in the United States and the above-cited observations. This paper describes the development of such a vaccine.

MATERIALS AND METHODS

Virus. Trinidad strain VEE virus had a history of one guinea pig passage followed by 13 passages in embryonated hens' eggs (12). The 13th egg passage material was grown in rolling-bottle cultures of chicken embryo cells (CEC) to produce seed virus for vaccine production. A 20% suspension of the 13th passage chicken embryo preparation was used as challenge virus for potency assays.

Virus titration. Three-week-old or 1- to 3-day-old white mice (CD-1 strain of Charles River Mouse Farms, Wilmington, Mass.) were inoculated intracerebrally (ic) with 0.03 ml of log_{10} dilutions of virus in cold phosphate-buffered saline (pH 7.2) containing 1% normal rabbit serum. Six mice were used for each dilution. After a 10-day observation period, titration end points were determined by the method of Reed and Muench (14) and are expressed as median lethal doses (LD_{50}) per ml.

Cell cultures. Rolling-bottle (280 mm; Belco Glass Inc., Vineland, N.J.) cultures of CEC were prepared as previously described (5). Cultures were incubated at 35°C until confluent cell sheets were obtained (18 to 24 hr). Growth medium was replaced with a maintenance medium (MM) consisting of serum-free medium 199 containing 0.25% human serum albumin (USP) plus 100 μg each of neomycin (USP) and streptomycin (USP) per ml, and the cultures were incubated an additional 20 to 24 hr at 35°C.

Inoculation of cell cultures. MM was decanted from cultures, and residual fluids were drained from the cell sheets. The infecting virus in 10 ml of MM
was added to each culture and adsorbed for 1 hr at 35 C with the roller apparatus set at 0.7 rev/min. To study the effect of multiplicity of inoculum (MOI), cultures were inoculated with VEE seed virus at MOI of 0.06 to 0.00006 (i.e., 0.06 to 0.00006 mouse LD<sub>50</sub> per cell) and maintained with 200 ml of MM. Culture fluid samples were removed at regular intervals postinoculation and were assayed as described. In all further studies herein, an MOI of 0.006 was employed; this was a 10<sup>-4</sup> dilution of the CEC virus seed material.

**Vaccine preparation.** Prior to inactivation, fluids from infected cultures were centrifuged at 1,000 x g for 30 min at 4 C and were then passed through a membrane filter (0.45-µm pore size; Millipore Corp., Bedford, Mass.) to remove cellular debris. Within 1 hr of filtration, Formalin (formaldehyde, 37% assay) was added to final concentrations of 1:2,000 (0.05%) or 1:1,000 (0.1%). After thorough mixing, the fluids in closed vessels were placed at 37 C in a reciprocating water bath (New Brunswick Scientific Co., Inc.) set at 150 rev/min. Fluids were thus kept in gentle, but constant movement throughout the inactivation periods of 24 to 96 hr. At the end of the desired period of inactivation, the material was held in closed vessels at 4 C for 15 days during which time the vessels were shaken at least twice daily.

**Assay of vaccines.** Potency was determined by using a one-dose antigen extinction assay in 3-week-old, CD-1 white mice. Groups of 10 mice were inoculated intraperitoneally (ip) on day 0 with 0.3 ml of fivefold dilutions of vaccine. Fourteen days later the mice were challenged ip with 10<sup>3</sup> to 10<sup>4</sup> mouse ip LD<sub>50</sub> of VEE virus. Animals were observed for 14 days; titration end points and median effective dose (ED<sub>50</sub>) values were determined as previously described (6).

**Tests for safety, toxicity, and sterility.** Representative lots of vaccine were tested in accordance with current U.S. government regulations (11). Testing was carried out as previously described (10).

**RESULTS**

**Virus replication.** Since similar virus yields were obtained at 20 and 24 hr postinoculation with all MOI tested (Table 1), a MOI of 0.006 was arbitrarily selected for use in subsequent experiments. This represented 10.0 ml of a 10<sup>-4</sup> dilution of seed virus having a titer of 10<sup>8.4</sup> mouse LD<sub>50</sub>/ml.

**Effect of volume of maintenance medium.** To determine the effect of MM volume on virus yield, replicate cultures were infected at a MOI of 0.006 and maintained with 100 to 300 ml of MM. Shown in Table 2 are the results of titrations performed with fluids removed from these cultures at regular intervals. Although adequate virus titers were achieved with all MM volumes between 12 and 24 hr postinoculation, substantially fewer cytopathic effects occurred in those cultures maintained with 300 ml of MM. In general, cell destruction was moderate at 12 to 18 hr, but increased greatly by 24 hr postinoculation.

**Virus inactivation.** Samples were taken at regular intervals during the period of inactivation and titrated immediately in 1- to 3-day-old mice. Control virus harvests subjected only to 37 C for similar periods were also included. Typical rates of inactivation for the two Formalin concentrations are shown in Table 3. With 0.05% Formalin, inactivation was complete between 8 to 10 hr. Use of 0.1% Formalin decreased the inactivation period to between 6 to 8 hr.

**Effect of Formalin concentration and length of inactivation period on vaccine potency.** Thirty small lots of VEE vaccine were prepared by using either 0.05 or 0.1% Formalin with inactivation periods of 24 to 96 hr. Table 4 is a summary of the results of single-dose potency assays performed on these vaccines. These data indicate that VEE virus is stable antigenically, even after treatment with 0.1% Formalin for 96 hr at 37 C. Selected lots of VEE vaccine were subjected to testing prior to final processing into multidose containers and were shown to be safe, sterile, and nontoxic.

**DISCUSSION**

The logistical advantages of the roller-bottle system for large-volume production of VEE vaccine is very evident. This method has been applied to other vaccines as well (13). The method has also been successfully applied to other systems where it is necessary to maintain a constant number of cells. This method is markedly superior to the traditional batch method in that it is not subject to the variability that is inherent in this system. The roller-bottle system is, however, subject to the limitations of the cell line used. This system can be adapted to a variety of other cell lines if they are available. The roller-bottle system is not without its limitations, however. It is not possible to control the cell density in a roller-bottle culture as accurately as in a batch culture. It is also possible to obtain a higher concentration of cells in a batch culture than in a roller-bottle culture. The roller-bottle system is not without its limitations, however. It is not possible to control the cell density in a roller-bottle culture as accurately as in a batch culture. It is also possible to obtain a higher concentration of cells in a batch culture than in a roller-bottle culture.

**TABLE 1. Effect of multiplicity of inoculum (MOI) on propagation of VEE virus in roller-bottle chicken embryo cell cultures**

| Hr post-inoculation | Log<sub>10</sub> LD<sub>50</sub>/ml by MOI of | 0.06 | 0.006 | 0.0006 | 0.00006 |
|---------------------|------------------------------------------|-------|-------|--------|---------|
| 20                  |                                          | 8.5   | 8.9   | 9.0    | 8.5     |
| 24                  |                                          | 8.7   | 9.3   | 8.5    | 9.0     |

* Multiplicity of inoculum, 0.006.

**TABLE 2. Effect of maintenance medium volume on propagation of VEE virus in chicken embryo cell roller-bottle cultures**

| Time (hr) postinoculation | Log<sub>10</sub> LD<sub>50</sub>/ml by maintenance medium volume* |
|---------------------------|---------------------------------------------------------------|
|                           | 100 ml | 200 ml | 300 ml |
| 2                         | 3.2    | 3.3    | 3.0    |
| 6                         | 6.5    | 6.3    | 6.0    |
| 12                        | 9.9    | 9.0    | 9.0    |
| 18                        | 9.9    | 10.3   | 9.9    |
| 24                        | 10.0   | 9.3    | 9.3    |

* Mean titers of samples obtained from replicate sets of cultures.
system in vaccine production were previously described (5). In the present study, we have used this technique to produce a potent, Formalin-inactivated VEE vaccine. As indicated by the results of studies in which various MOI were employed, great latitude is possible in selection of virus input. These results in concert with those obtained in the evaluation of the effect of MM volumes indicate that virus material of high titer could easily be obtained with a convenient 18 to 24 hr harvest time. Use of larger volumes of MM resulted in decreased cell destruction and therefore would insure minimal carry-over of cellular material into the final product. Thus, by careful selection of virus input and MM volume, one can adjust the system to comply with production schedules as desired.

Our studies on Formalin inactivation at 37 C showed that although Trinidad strain VEE virus is resistant to heat inactivation, it is readily inactivated by both 0.05% and 0.1% Formalin at 37 C. Live virus was not detectable after 10 hr with 0.05% Formalin, or after 8 hr with 0.1%.

Recently, other authors (8, 15) noted the work of Smith, et al. (17) with regard to the inability to detect residual live virus in certain lots of VEE vaccines prepared from infected chicken embryos by Randall, Mills, and Engel (13), even though these same lots of vaccine had caused infection in 4% of 327 human vaccinees. Employing the best vaccine production techniques then available (13), these early workers attempted to inactivate the virus with 0.3% Formalin at 21 C for 4 days with periodic shaking of the vessel. The starting material was a crude 30% suspension of infected chicken embryos containing approximately 2 mg of protein N per ml. It is also significant that no filtration was employed to remove cellular debris. Furthermore, the authors described the final purified product, prepared by Sharples centrifugation as "...a pale yellow, slightly turbid fluid ..." (13). All of these data strongly suggest that the virus was protected from the action of the Formalin as proposed by Smith et al. (17), perhaps by the location of the virus within cells or cellular debris. There was thus a possibility for the "unmasking" of the virus in man after vaccination.

In contrast, our method of inactivation consisted of the addition of 0.05 or 0.1% Formalin to a centrifuged and filtered, optically clear cell culture harvest that contained 0.29 to 0.38 mg of protein N per ml, the majority of which was the 0.25% human serum albumin added as a stabilizer (unpublished data). Thus, far less protein and little or no cellular debris were present to protect the virus. We inactivated at

**TABLE 3. Formalin inactivation of VEE virus at 37 C**

| Time (hr) after Formalin | Log10 LD50/0.03 ml by Formalin concn of | Virus control * |
|-------------------------|----------------------------------------|-----------------|
|                         | 0.05%  | 0.1%  |                  |                 |
| 0                       | 8.7  | 8.7  | 8.7              |                 |
| 1                       | 5.0  | 4.5  |                  |                 |
| 2                       | 2.7  | 2.2  |                  |                 |
| 3                       | 1.5  | <1.0 |                  |                 |
| 4                       | 1.0  | <1.0 |                  |                 |
| 5                       | <1.0 | <1.0 |                  |                 |
| 6                       | <1.0 | <1.0 |                  |                 |
| 8                       | <1.0 | 0    |                  |                 |
| 10                      | 0    | 0    |                  |                 |
| 12                      | 0    | 0    |                  |                 |
| 14                      | 0    | 0    |                  |                 |
| 16                      | 0    | 0    |                  |                 |
| 24                      | 0    | 0    | 7.2              | 1.5            |
| 96                      |      |      |                  |                 |

* Determined by ic inoculation of 1- to 3-day-old mice with 0.03 ml.
* Virus subjected to 37 C only.
* Blanks, not tested.
* Indicates survival of 50/50 mice inoculated with undiluted vaccine.

**TABLE 4. Effect of Formalin concentration and length of inactivation period on potency of VEE vaccines**

| Formalin concn (%) | Median effective dose (ml) by hr of inactivation |
|--------------------|-----------------------------------------------|
|                    | 24  | 30  | 48  | 72  | 96  |
| 0.05               | 0.032* | 0.040* | 0.032 | 0.021 | 0.012* |
|                    | (0.026-0.042) | (0.0072-0.11) | (0.0039-0.030) | (0.0041-0.019) | (0.0054-0.034) |
| 0.1                | 0.015 | 0.017* | 0.026 | 0.0081 | 0.014* |

* Mean of three lots; values in parentheses indicate range of value for ED50; when no range is shown, only one lot was tested.
* Mean of 12 lots.
* Mean of four lots.
* Mean of two lots.
37 C with the vessels kept in constant motion throughout the periods employed. Other investigators have shown that temperature is critical and that lower temperatures greatly decrease the rate of inactivation (7, 16, 18).

In future studies, selected lots of inactivated Trinidad VEE vaccine will be tested in Equidae to establish parameters for volume and number of doses required, interval between doses, persistence of immunity, and effectiveness as a "booster" in equines previously immunized with attenuated VEE vaccine as well as in offspring of the latter.

LITERATURE CITED
1. Alevizatos, A. C., R. W. McKinney, and R. D. Feigin. 1967. Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Amer. J. Trop. Med. Hyg. 16:762-768.
2. Bartelloni, P. J., R. W. McKinney, F. M. Calia, H. R. Ramsburg, and F. E. Cole, Jr. 1971. Inactivated Western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serologic evaluation in man. Amer. J. Trop. Med. Hyg. 20:146-149.
3. Bartelloni, P. J., R. W. McKinney, T. P. Duffy, and F. E. Cole, Jr. 1970. An inactivated Eastern equine encephalomyelitis vaccine propagated in chick embryo cell culture. II. Clinical and serologic responses in man. Amer. J. Trop. Med. Hyg. 19:123-126.
4. Berge, T. O., I. S. Banks, and W. D. Tigertt. 1961. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells. Amer. J. Hyg. 73:209-218.
5. Cole, F. E., Jr. 1971. Inactivated Eastern equine encephalomyelitis vaccine propagated in rolling-bottle cultures of chick embryo cells. Appl. Microbiol. 21:842-845.
6. Cole, F. E., Jr., and R. W. McKinney. 1969. Use of hamsters for potency assay of Eastern and Western equine encephalitis vaccine. Appl. Microbiol. 17:927-928.
7. Darwish, M. A., and W. McD. Hammon. 1966. Japanese B encephalitis virus vaccines from tissue culture. VII. Formalin inactivated Nakayama strain vaccine. Proc. Soc. Exp. Biol. Med. 122:813-816.
8. Gruber, J. 1971. Immunogenicity of purified Venezuelan equine encephalitis virus isolated by ionizing radiation. Infect. Immunity 3:574-579.
9. McKinney, R. W., T. O. Berge, W. D. Sawyer, W. D. Tigertt, and D. Crozier. 1963. Use of an attenuated strain of Venezuelan equine encephalomyelitis virus for immunization in man. Amer. J. Trop. Med. Hyg. 12:597-603.
10. Maire, L. F., III, R. W. McKinney, and F. E. Cole, Jr. 1970. An inactivated Eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. I. Production and testing. Amer. J. Trop. Med. Hyg. 19:119-122.
11. Public Health Service. 1971. Regulations for the manufacture of biological products. U.S. Public Health Service Title 42, Part 73.
12. Randall, R., and J. W. Mills. 1944. Fatal encephalitis in man due to the Venezuelan virus of equine encephalomyelitis in Trinidad. Science 99:225-226.
13. Randall, R., J. W. Mills, and L. L. Engel. 1947. The preparation and properties of a purified equine encephalomyelitis vaccine. J. Immunol. 55:41-52.
14. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Amer. J. Hyg. 27:493-497.
15. Reitman, M., H. R. Tribble, Jr., and L. Green. 1970. Gamma-irradiated Venezuelan equine encephalitis vaccines. Appl. Microbiol. 19:763-767.
16. Robinson, D. M., S. Berman, J. P. Lowenthal, and F. M. Hetrick. 1966. Western equine encephalomyelitis vaccine produced in chick embryo cell cultures. Appl. Microbiol. 14:1011-1014.
17. Smith, D. G., H. K. Marnay, R. G. Marshall, and J. C. Wagner. 1956. Venezuelan equine encephalomyelitis. Laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine. Amer. J. Hyg. 63:150-164.
18. White, A., S. Berman, and J. P. Lowenthal. 1971. Inactivated Eastern equine encephalomyelitis vaccines prepared in monolayer and concentrated suspension chick embryo culture. Appl. Microbiol. 22:909-913.